The present invention relates to a technique for effective intranasal delivery to the brain. More specifically, the present invention is used for diagnosing, preventing or treating central nervous system encephalopathy, neurodegenerative diseases or brain tumor by effectively delivering to the brain a pH-responsive and bioreducible PPA polymer, which can be used as a drug carrier, by means of nasal administration.

Provided are a composition and a sheet, including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support and a preparing method thereof. More specifically, in the sheet including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support according to the present invention, the high-active mesenchymal stem cells may be applied to a wounded part of a patient with epidermolysis bullosa as it is without isolation using proteases, and in the culturing, an extracellular matrix such as collagen, laminin, fibronectin, and elastin secreted from the mesenchymal stem cells is wholly present on the hydrogel to have an advantageous effect that skin reproduction and re-epithelization abilities are significantly excellent as compared with conventional dressing agents used for epidermolysis bullosa.

Provided are a composition and a sheet, including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support and a preparing method thereof. More specifically, in the sheet including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support according to the present invention, the high-active mesenchymal stem cells may be applied to a wounded part of a patient with epidermolysis bullosa as it is without isolation using proteases, and in the culturing, an extracellular matrix such as collagen, laminin, fibronectin, and elastin secreted from the mesenchymal stem cells is wholly present on the hydrogel to have an advantageous effect that skin reproduction and re-epithelization abilities are significantly excellent as compared with conventional dressing agents used for epidermolysis bullosa.

Composite materials, specifically to materials used in medicine, in particular, in ophthalmology for the manufacturing of optical ophthalmic implants, mainly intraocular lenses (IOL), intended for vision correction after cataract removal. The polymerization rate of the material is controlled in order to eliminate defects in the ophthalmic implant profile, control the geometric dimensions, reduce the finished product glistening while keeping optimal physical and mechanical properties. The material for the manufacturing of ophthalmic implants by photo-polymerization method includes: a) 60-70 wt. % oligomer of urethanedi(meth)acrylate with terminal (meth)acrylate fragments; b) 20-40 wt. % of (meth)acrylate monomers with aromatic substituents in the side chain; c) 5-25 wt. % of (meth)acrylate monomers with aliphatic branched substituents in the side chain; d) at least 0.2 wt. % of a UV-absorbing component; e) 0.1 to 1 wt. % of photopolymerization initiator; and f) 0.005 to 0.5 wt. % of a radical polymerization inhibitor.

The present invention relates to compositions and methods for the delivery of agents to a subject, particularly to the central nervous system (CNS).

The present invention relates to compositions and methods for the delivery of agents to a subject, particularly to the central nervous system (CNS).

The present invention relates to sugar-derived catanionic surfactant vesicles comprising anti-inflammatory dendrimers and to their use as a medicament, more particularly in the treatment of psoriasis.

The present invention relates to sugar-derived catanionic surfactant vesicles comprising anti-inflammatory dendrimers and to their use as a medicament, more particularly in the treatment of psoriasis.

The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a tissue that is impacted by a disease that is treatable with CSF1/CSF1R inhibition and/or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.

The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.